Shares of Express Scripts Holding Co (NASDAQ:ESRX) have been given an average recommendation of “Hold” by the eighteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $93.41.

A number of equities research analysts have commented on the company. BidaskClub upgraded Express Scripts from a “hold” rating to a “buy” rating in a research note on Tuesday, September 18th. Barclays raised their target price on Express Scripts from $83.00 to $90.00 and gave the stock an “equal weight” rating in a report on Thursday, November 1st. Maxim Group reissued a “hold” rating on shares of Express Scripts in a report on Thursday, November 1st. Zacks Investment Research raised Express Scripts from a “hold” rating to a “buy” rating and set a $111.00 price objective on the stock in a report on Friday, December 14th. Finally, Mizuho set a $101.00 price objective on Express Scripts and gave the company a “hold” rating in a report on Monday, November 5th.

In other news, Director Mahon Thomas P. Mac sold 5,234 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $99.50, for a total value of $520,783.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.79% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESRX. Csenge Advisory Group purchased a new position in shares of Express Scripts in the third quarter valued at approximately $30,000. Rehmann Capital Advisory Group lifted its position in shares of Express Scripts by 29.7% in the third quarter. Rehmann Capital Advisory Group now owns 529 shares of the company’s stock valued at $50,000 after acquiring an additional 121 shares in the last quarter. TRUE Private Wealth Advisors purchased a new position in shares of Express Scripts in the third quarter valued at approximately $115,000. Palo Capital Inc. purchased a new position in shares of Express Scripts in the third quarter valued at approximately $124,000. Finally, BDO Wealth Advisors LLC lifted its position in Express Scripts by 124.8% during the second quarter. BDO Wealth Advisors LLC now owns 1,639 shares of the company’s stock worth $127,000 after buying an additional 910 shares in the last quarter. Institutional investors and hedge funds own 84.87% of the company’s stock.

Express Scripts stock traded down $3.47 during mid-day trading on Friday, hitting $92.33. The company’s stock had a trading volume of 31,612,912 shares, compared to its average volume of 6,636,970. The company has a market capitalization of $52.06 billion, a PE ratio of 13.00, a price-to-earnings-growth ratio of 1.16 and a beta of 0.88. The company has a quick ratio of 0.65, a current ratio of 0.77 and a debt-to-equity ratio of 0.63. Express Scripts has a one year low of $66.93 and a one year high of $101.73.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $2.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.01. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. The company had revenue of $25.56 billion for the quarter, compared to the consensus estimate of $25.11 billion. During the same quarter in the prior year, the company posted $2.51 EPS. Express Scripts’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, research analysts anticipate that Express Scripts will post 9.08 earnings per share for the current year.

Express Scripts Company Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

See Also: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.